2-HOBA treatment for pulmonary hypertension
2-HOBA for Treatment of Pulmonary Hypertension
People with pulmonary hypertension will receive the drug 2-HOBA to try to lower pressure in the lung blood vessels and help the heart work better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mti Biotech, INC. NIH-funded |
| Lab location | 1 site (Ames, United States) |
| Project ID | NIH-11180471 on NIH RePORTER |
What this research studies
This Phase II project gives people with pulmonary hypertension an oral drug called 2-HOBA that soaks up reactive lipid molecules thought to damage mitochondria and drive the disease. Researchers will build on cell, animal, and Phase I human safety data and treat participants while monitoring symptoms, lung blood flow and resistance, heart function under stress, and blood biomarkers. Study procedures will include regular clinic visits, hemodynamic testing, imaging, and laboratory tests to track safety and biological effects. The data will be used to support potential commercialization and larger trials if results are promising.
Who could benefit from this research
Good fit: Adults with Group I or II pulmonary hypertension who are medically stable and able to attend clinic visits and testing are the most likely candidates.
Not a fit: People whose pulmonary hypertension is caused by conditions not targeted by this drug mechanism, or those with severe organ failure or other contraindications, may not benefit or be eligible.
Why it matters
Potential benefit: If successful, 2-HOBA could lower pulmonary vascular resistance, reduce harmful inflammation, and improve heart function in people with pulmonary hypertension.
How similar studies have performed: Early animal studies and Phase I human data showed safety and signals of reduced pulmonary vascular resistance and biomarker changes, so the approach has encouraging preliminary evidence but needs Phase II proof.
Where this research is happening
Ames, United States
- Mti Biotech, INC. — Ames, United States (Active)
Researchers
- Principal investigator: Rathmacher, John a — Mti Biotech, INC.
- Study coordinator: Rathmacher, John a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.